How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

597 results for

Melasma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Quality of life in patients with melasma in Turkish women (PubMed)

Quality of life in patients with melasma in Turkish women 29430289 2019 02 26 2036-7392 9 2 2017 Oct 11 Dermatology reports Dermatol Reports Quality of life in patients with melasma in Turkish women. 7340 10.4081/dr.2017.7340 Uyanikoglu Hacer H Department of Obstetrics and Gynecology. Aksoy Mustafa M Department of Dermatology, Harran University Medical Faculty, Sanliurfa, Turkey. eng Case Reports 2017 10 10 Italy Dermatol Reports 101566470 2036-7392 Quality of life Turkish women melasma 2017 09

Full Text available with Trip Pro

2017 Dermatology Reports

82. The Asian Problem of Frequent Laser Toning for Melasma (PubMed)

The Asian Problem of Frequent Laser Toning for Melasma In recent years, laser toning or laser facial to treat melasma has become increasingly popular in Asia. It is common to see patients undergoing lasers three times a week, or even daily. This is part of a growing trend and is sometimes recommended in the user manuals from laser manufacturers. In our study, we report on 23 Chinese patients who had lasers performed three times a week for two consecutive months, followed by rest. All 23 of them

Full Text available with Trip Pro

2017 The Journal of clinical and aesthetic dermatology

83. Melasma: an Up-to-Date Comprehensive Review (PubMed)

Melasma: an Up-to-Date Comprehensive Review Melasma is a common acquired condition of symmetric hyperpigmentation, typically occurring on the face, with higher prevalence in females and darker skin types. Multiple etiologies, including light exposure, hormonal influences, and family history, have been implicated in the pathogenesis of this disorder. Overall prevalence ranges widely at 1-50%, since values are typically calculated within a specific ethnic population within a geographic region (...) . Histologically, melasma can display increased epidermal and/or dermal pigmentation, enlarged melanocytes, increased melanosomes, solar elastosis, dermal blood vessels, and, occasionally, perivascular lymphohistiocytic infiltrates. Various topical, oral, and procedural therapies have been successfully used to treat melasma. Traditional topical therapies including hydroquinone, tretinoin, corticosteroids, and triple combination creams; however, other synthetic and natural topical compounds have also shown

Full Text available with Trip Pro

2017 Dermatology and therapy

84. Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2016 Clinical Trials

85. Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical (...) Composition Therapy (2013-MCN-333) for the Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02730819 Recruitment Status : Completed First Posted : April 7, 2016 Results First Posted : September 20, 2017 Last Update Posted : October 20, 2017 Sponsor: Mayo Clinic Information provided

2016 Clinical Trials

86. Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma

Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02892071 Recruitment Status : Not yet recruiting First Posted : September 8, 2016

2016 Clinical Trials

87. 1064-nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma

1064-nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma 1064-nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 1064 (...) -nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03008655 Recruitment Status : Unknown Verified December 2016 by Huang Yu Chen, Taipei Medical University WanFang Hospital. Recruitment status was: Not yet recruiting First Posted

2016 Clinical Trials

88. Reliability, Validity, and Sensitivity to Change Overtime of the Modified Melasma Area and Severity Index Score. (PubMed)

Reliability, Validity, and Sensitivity to Change Overtime of the Modified Melasma Area and Severity Index Score. The new modified Melasma Area and Severity Index (mMASI) score, the recently used outcome measure for melasma, has not been tested to determine its sensitivity to change in melasma.To determine the reliability, validity, and sensitivity to change overtime of the mMASI score in assessment of the severity of melasma.Pearson correlation, Cronbach alpha, and intraclass correlation (...) coefficient were calculated to assess the reliability of the mMASI score. Validity of the mMASI scale was carried out using Spearman correlation between mMASI total score (before and after treatment), clinical data, and patient's responses.The mMASI score showed excellent reliability and good validity for assessment of the severity of melasma. The authors also determined that the mMASI score demonstrated sensitivity to change over time.An excellent degree of agreement between the mMSAI and MASI scores

Full Text available with Trip Pro

2016 Dermatologic Surgery

89. A review of melasma treatment focusing on laser and light devices. (PubMed)

A review of melasma treatment focusing on laser and light devices. Melasma is a pigmentary disorder of unclear etiology with numerous treatment options and high recurrence rates. Laser and light therapies may be utilized cautiously as second- or third-line options for recalcitrant melasma, but low-energy settings are preferred due to the risk of postinflammatory hyperpigmentation and melasma stimulation. Commonly used lasers include the low-fluence 1064-nm Q-switched neodymium-doped yttrium

2016 Seminars in Cutaneous Medicine and Surgery

90. The Effect of Topical Use of Petroselinum Crispum (Parsley) Versus That of Hydroquinone Cream on Reduction of Epidermal Melasma: A Randomized Clinical Trial. (PubMed)

The Effect of Topical Use of Petroselinum Crispum (Parsley) Versus That of Hydroquinone Cream on Reduction of Epidermal Melasma: A Randomized Clinical Trial. Melasma disfigures the skin and thus influences people's self-image and self-concept. Therefore, melasma influences emotional and psychosocial health in addition to physical health. This clinical trial was performed to assess the effect of the topical use of Petroselinum crispum (parsley) on reduction of the severity of epidermal melasma.

2016 Holistic nursing practice

91. Efficacy and possible mechanisms of topical tranexamic acid in melasma. (PubMed)

Efficacy and possible mechanisms of topical tranexamic acid in melasma. Tranexamic acid (TA) has been suggested as an effective treatment for melasma.To investigate the effects and mechanism of action of topical TA in the treatment of melasma.In this study, 23 participants with melasma applied a 2% TA formulation to the whole face for 12 weeks. Clinical effects were evaluated using the modified Melasma Area and Severity Index (mMASI) and a chromameter. Skin biopsies were obtained from 10 (...) participants to evaluate pigmentation, vascularity and the expression levels of possible paracrine factors contributing to the effect of TA.Most of the participants had mild melasma, with mMASI of < 5. The mMASI scores significantly improved in 22 of 23 participants after application. The L* values were increased and the a* values were decreased in both lesional and perilesional normal skin. Fontana-Masson staining showed a significant decrease in melanin content in the epidermis. The number of CD31

2016 Clinical & Experimental Dermatology

92. Clinical and Histopathologic Assessment of Facial Melasma After Low-Fluence QS Nd: YAG Laser. (PubMed)

Clinical and Histopathologic Assessment of Facial Melasma After Low-Fluence QS Nd: YAG Laser. Melasma is a frequent and difficult to treat skin disorder. Results of laser therapy are inconsistent.To determine the safety and efficacy of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (QS Nd:YAG) laser for melasma treatment and assess recurrence rates and histopathologic findings before and after treatment.Twenty patients were treated with 10 weekly sessions of low-fluence 1064-nm (...) QS Nd:YAG laser at 1-week intervals. The modified Melasma Area and Severity Index (mMASI) score was evaluated at baseline; 1 week; and 1, 3, and 6 months after treatment. Epidermal melanin quantification was performed on 10 biopsy samples and compared before and after treatment.All patients showed improvement by mMASI scores, range (21%-75%) compared with that at baseline. No permanent side effects occurred. The recurrence rate was 81%. By histopathology, a slight, nonsignificant (p = .305

2016 Dermatologic Surgery

93. Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma. (PubMed)

Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma. Melasma is a common acquired skin disorder. While different treatments are currently being used, in many cases it is refractory to treatment. According to the effects of topical steroids in decreasing skin pigmentation, we studied the efficacy of this new method for treatment of melasma. A total of 42 women with facial melasma, admitted to the department of dermatology of Hamadan, were enrolled (...) in the study. They were divided randomly into two groups (A and B), group A (case) received subepidermal triamcinolone injections with a dose of 4 mg per cc and 5 mm intervals until complete blanching of melasma lesions, and group B (control) received Kligman's formula (hydroquinone 5%, tretinoin 0.1%, and dexamethasone 0.1%). At the first visit, we completed the MASI score papers, and we repeated that at weeks 4 and 8 of the study. We followed them for two months, every two weeks. At each visit, side

2016 Acta medica Iranica

94. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. (PubMed)

Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. Melasma is a common pigmentary disorder among Asians and treatment is challenging. Oral tranexamic acid (TA) has emerged as a potential treatment for refractory melasma. Large-scale studies on its use, outcomes, and safety are limited.We sought to evaluate treatment outcomes and adverse effects of oral TA in melasma in an Asian population.We conducted a retrospective analysis of patients who received oral TA (...) for melasma in a tertiary dermatologic center from January 2010 to June 2014.In all, 561 patients (91.4% female, 8.6% male) were enrolled. Median duration of treatment was 4 months. The majority (503 [89.7%]) improved, 56 (10.0%) had no improvement, and 2 (0.4%) worsened. Patients without family history of melasma had better response rates than those with family history (90.6% vs 60.0%, P = .01). Of the 503 who improved, response was seen within 2 months of TA initiation, with a relapse rate of 27.2

2016 Journal of American Academy of Dermatology

95. Oral tranexamic acid lightens refractory melasma. (PubMed)

Oral tranexamic acid lightens refractory melasma. Melasma is a common acquired hyperpigmentary disorder, particularly among Asians and Hispanics, but its exact pathomechanism is poorly understood. Tranexamic acid has been found to lighten melasma by interfering with the interaction of melanocytes and keratinocytes by inhibiting the plasminogen/plasmin system. The aim was to evaluate the therapeutic effects of oral tranexamic acid in the treatment of melasma refractory to topical skin-lightening (...) agents.This retrospective study analyses patients with melasma recruited from a tertiary dermatological centre in Singapore between 1 August 2009 and 31 March 2011. The patients chosen had refractory melasma treated with oral tranexamic acid 250 mg twice daily in addition to pre-existing combination topical therapy. Objective assessment using the physician's global assessment and melasma area and severity index (MASI) scores were performed based on a post-hoc analysis of photographic records by three

2016 Australasian Journal of Dermatology

96. Melasma

Melasma Melasma Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Melasma Melasma Aka: Melasma , Chloasma , Mask of pregnancy From (...) Related Chapters II. Definition Chloasma from Greek: "Greenish tint of growing bud" III. Epidemiology Women outnumber men by 9:1 ratio More prominent with darker skin (skin types 4-6) IV. Causes Pregnancy (affects 70% of pregnant women) See Usually during second and third trimesters Resolves after delivery Often darker with subsequent pregnancies s (e.g. ) disease V. Signs Progressive r, nonscaling hypermelanosis on skin that is sun exposed Hyperpigmented brown flat r patch Epidermal Melasma: Light

2018 FP Notebook

97. Randomized clinical trial of facial acupuncture with or without body acupuncture for treatment of melasma. (PubMed)

Randomized clinical trial of facial acupuncture with or without body acupuncture for treatment of melasma. To evaluate the efficacy of acupuncture treatments in treating facial melasma, contrasting treatments involving facial acupuncture with facial/body acupuncture.Women suffering with melasma were randomly assigned into: 1) facial acupuncture (n = 20); or 2) facial/body acupuncture (n = 21). Each group was given 2 sessions per week for 8 weeks. Melasma area and darkness of its pigmentation (...) were assessed using digital images.95.2% and 90% of participants in facial/body and facial acupuncture, respectively, had decreased melasma areas, with a mean reduction area being 2.6 cm(2) (95%CI 1.6-3.6 cm(2)) and 2.4 cm(2) (95%CI 1.6-3.3 cm(2)), respectively. 66.7% (facial/body acupuncture) and 80.0% (facial acupuncture) of participants had lighter melasma pigmentation compared to their baselines (p-value = 0.482).Facial acupuncture, with or without body acupuncture, was shown to be effective

2016 Complementary Therapies in Clinical Practice

98. Comparative Evaluation of Efficacy and Tolerability of Glycolic Acid, Salicylic Mandelic Acid, and Phytic Acid Combination Peels in Melasma. (PubMed)

Comparative Evaluation of Efficacy and Tolerability of Glycolic Acid, Salicylic Mandelic Acid, and Phytic Acid Combination Peels in Melasma. Melasma is acquired symmetric hypermelanosis characterized by light-to-deep brown pigmentation over cheeks, forehead, upper lip, and nose. Treatment of this condition is difficult and associated with high recurrence rates. Chemical peels have become a popular modality in the treatment of melasma.To compare the therapeutic efficacy and tolerability (...) of glycolic acid (35%) versus salicylic-mandelic (SM) acid (20% salicylic/10% mandelic acid) versus phytic combination peels in Indian patients with melasma.Ninety patients diagnosed with melasma were randomly assigned into 3 groups of 30 patients each. Group A received glycolic acid (GA-35%) peel, Group B received SM acid, and Group C received phytic combination peels. Each group was primed with 4% hydroquinone and 0.05% tretinoin cream for 4 weeks before treatment. Chemical peeling was done after every

2016 Dermatologic Surgery

99. A Retrospective Analysis of the Treatment of Melasma Using a Fractional Long-Pulsed Alexandrite Laser in Korean Patients. (PubMed)

A Retrospective Analysis of the Treatment of Melasma Using a Fractional Long-Pulsed Alexandrite Laser in Korean Patients. Long-pulsed, 755-nm, alexandrite lasers have been shown to be effective and safe in the treatment of pigmentary lesions.Clinical outcomes and side effects in the treatment of melasma using a fractional, long-pulsed, alexandrite laser were assessed.Forty-eight patients with melasma received 2 to 4 treatment sessions of fractional, long-pulsed, alexandrite laser at 2 to 3 (...) weeks intervals. The parameter of treatment was 60 to 80 J/cm without dynamic cooling device using 15-mm spot size of fractional hand piece, with a 0.5- to 1-millisecond pulse width.The mean modified melasma area and severity index score decreased significantly 2 months after the final treatment compared with baseline (16.5 ± 8.2 vs 11.5 ± 7.0; p = .002). The patients with epidermal type melasma were more effective compared to dermal type (p < .001).Long-pulsed alexandrite lasers using a fractional

2016 Dermatologic Surgery

100. Role of fibroblast-derived factors in the pathogenesis of melasma. (PubMed)

Role of fibroblast-derived factors in the pathogenesis of melasma. The hyperactive melanocytes present in melasma skin are confined to the epidermis, but epidermal ablation to treat melasma pigmentation may lead to disease recurrence and aggravation. Melanocyte function is regulated by interactions between melanocytes and neighbouring cells such as keratinocytes and fibroblasts. Because melasma skin usually shows dermal changes after exposure to sunlight, we hypothesized that sun-damaged (...) fibroblasts might play a crucial role in the pathogenesis of melasma.In this study, the melanogenic role of primary cultured fibroblasts from human melasma skin was investigated.We explored whether primary cultured fibroblasts from melasma tissue have a melanogenic function on cultured human epidermal melanocytes and artificial skin. The cytokine profile derived from fibroblasts and their effect on the pigmented epidermal equivalents were investigated.Fibroblasts from the melasma lesion and perilesional

2016 Clinical & Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>